Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo


CIHR-Funded Strategy For Patient Oriented Research (SPOR)


Paul Moayyedi is the Nominated Principal Investigator for a CIHR-funded Strategy for Patient-Oriented Research (SPOR) chronic disease network termed the Inflammation, Microbiome and Alimentation: Gastro-intestinal and Neuropsychiatric Effects (IMAGINE) network (  This is a $40 million funded project that will study how diet and the gut microbiome interact to cause both inflammatory bowel disease and irritable bowel syndrome and associated psychiatric disorders.  The aim of the network is to explore new dietary interventions and therapies aimed at altering the gut microbiome to influence these diseases as well as develop personalized medicine approaches to treating IBD and IBS.  He also conducted the first randomized trial that showed that fecal microbial transplant can be successful at inducing remission in ulcerative colitis.  This work was subsequently confirmed by other researchers.

Expandable List


Dr. Moayyedi is on the ClarivateTM Highly Cited ResearchersTM 2022 list of the top 0.1% of world researchers from the last decade and his work has been cited over 70,000 times.  He has been the principal investigator or co-applicant on grants totalling over $100,000,000.  He was the co-Editor-in Chief (EIC) of the American Journal of Gastroenterology 2010-2015 with Dr Wiliam D Chey and is currently the co-Editor-in-Chief of Gastroenterology with Dr David S Weinberg. He is the only person to be appointed to these journals outside of the US and is the only person who has been EIC of both these prestigious GI journals.  He is currently the President of the Canadian Association of Gastroenterology.


  1. Ford AC, Tsipotis E, Yuan Y, Leontiadis GI, Moayyedi P. Efficacy of Helicobacter pylorieradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut 2022; 71: 1967-75.
  2. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019; 157: 682-91.
  3. Moayyedi P, MacQueen G, Bernstein CN, Vanner S, Bercik P et al. IMAGINE Network’s Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open 2020; 10: e041733 DOI: 10.1136/bmjopen-2020-041733
  4. Jankowski JA, de Caestecker J, Love SB …. Moayyedi P. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet 2018; 392: 400-8.
  5. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.  Gastroenterology 2015; 149: 102-9.